Safe storage at home

Keeping medicinal cannabis secure in a New Zealand home is not about hiding it from visitors. It is about preventing three specific harms: a child or pet finding it, accidental consumption by an adult, and legal exposure for the person named on the dispensing label. Under the Misuse of Drugs Act 1975, medicinal cannabis is a controlled prescription medicine, and the way you store it is part of your legal responsibility as the patient or caregiver. The one sentence no other page can write: A New Zealand prescription for medicinal cannabis does not create a general licence to keep it anywhere, and if a child, visitor or pet accesses your product, you can face legal liability under the Misuse of Drugs Act 1975.

The one rule that changes everything

Store all medicinal cannabis flower, oils, capsules and edibles in a locked container, out of sight, in a cool, dark place, and never in a location a child or pet can reach. That is the entire method. The rest is detail about how to make that rule work in a real home.

The reason this matters is not just safety; it is legal. In New Zealand, medicinal cannabis is a controlled medicine under the Misuse of Drugs Act 1975, and the Medicinal Cannabis Scheme sets the conditions for lawful possession and use. A prescription does not create a general licence to keep cannabis anywhere. If a child, visitor or pet accesses the product, you can face legal liability, and more importantly, a child can be seriously harmed by ingesting even a small amount of THC. The law does not require a locked safe for personal medicinal use, but the Misuse of Drugs Regulations 1977 (as amended) require that controlled drugs be kept in a manner that prevents access by unauthorised persons. For practical purposes, that means a lockable container or cabinet, not a kitchen drawer.

What “safe storage” means under New Zealand law

Under the Misuse of Drugs Act 1975, medicinal cannabis items are controlled drugs. The Medicinal Cannabis Scheme (Misuse of Drugs (Medicinal Cannabis) Regulations 2019) sets the legal pathway for prescribing, dispensing and possession. The Ministry of Health (2023) states that a patient with a valid authorisation may possess and use medicinal cannabis, but the product must be a controlled drug as defined in the rules, meaning it must meet GMP standards and be approved by the Ministry. The legal framework does not create a general right to possess cannabis; it only covers the prescribed product.

The practical implication for storage: the legal obligation to store securely sits with the patient or caregiver. The Misuse of Drugs Regulations 1977 (as amended) require that controlled drugs be kept in a safe and secure place, and while this is not a locked safe by law for personal use, the expectation under the Medicinal Cannabis Scheme is that the product is not accessible to children or unauthorised persons. In practice, this means a lockable container, out of sight and reach, and never in a treat jar or open bowl.

Medsafe (the New Zealand Medicines and Medical Devices Safety Authority) is the regulator that approves finished medicinal cannabis items under the Medicinal Cannabis Scheme. Products must meet GMP standards, and the Medicinal Cannabis Agency (MCA) manages licences and quality. A medical practitioner must issue the authorisation; it is not a general licence to use cannabis.

How the prescribing pathway works

The prescribing pathway starts with a consultation with a medical practitioner (a specialist or a GP with appropriate training) who can prescribe under the Misuse of Drugs Act. The prescriber must consider the NZ Formulary guidance and the patient’s condition; they may need to apply for approval under Section 29 of the Misuse of Drugs Act if the item is not already approved. All prescribed cannabis must be manufactured to GMP (Good Manufacturing Practice) standards and be approved by the Ministry of Health under the Medicinal Cannabis Scheme. The scheme’s legal basis is the Misuse of Drugs Act 1975 and the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, which came into force on 1 April 2020. The Medicinal Cannabis Agency, part of Medsafe, oversees the scheme.

Only a medical practitioner can prescribe. Nurse practitioners cannot prescribe cannabis unless they are registered with the Medical Sciences Secretariat. Specialists can prescribe, and GPs can prescribe, but GPs may not have enough training or confidence; the prescribing decision is clinical, not administrative. The NZ Formulary lists cannabis items, but it is not a licence to prescribe freely; prescribers must follow the Misuse of Drugs Regulations 1977 and the Misuse of Drugs (Medicinal Cannabis) Regulations 2019.

Product categories and what they mean for storage

Medicinal cannabis in this country is divided into two main categories: those containing THC (delta-9-tetrahydrocannabinol) and those containing CBD (cannabidiol). THC is the psychoactive compound; CBD is not psychoactive. Items are dispensed as oils, capsules or dried flower for inhalation. The choice between flower and oil is not about legality (both are legal when prescribed) but about onset and duration: inhaled flower acts in 5-10 minutes and lasts 2-4 hours; oral oils act in 30-90 minutes and last 6-8 hours.

The main product types are: - CBD-dominant (e.g., CBD100): low or no THC, non-psychoactive, used for anxiety, inflammation and chronic pain. - Balanced (e.g., THC10:CBD10): roughly equal THC and CBD, used for pain where some psychoactivity is acceptable. - THC-dominant (e.g., THC25): high psychoactivity, used for severe pain, nausea or sleep when other options fail. - Isolates (e.g., Cannabisol 100): pure CBD, no THC; used when patients want to avoid any psychoactive effect. - Full-spectrum vs isolate: full-spectrum contains multiple cannabinoids and terpenes; isolates contain only one. Evidence for the entourage effect is still limited.

All items require a valid authorisation from a registered medical practitioner; there is no OTC access in this jurisdiction. They must be GMP-certified and approved by the Ministry of Health; unapproved items are illegal. THC content is capped at 0.3% for hemp-derived CBD items, but medicinal cannabis can exceed this with a practitioner’s order.

THC content is not the only factor; the ratio of THC to CBD matters. Patients with anxiety often prefer high-CBD, while those with severe pain often need higher THC. In practice, a GP will start low and go slow, and the patient should track symptoms daily. CBD is not a sedative at low doses; it is often alerting. Patients who take CBD for sleep may find it keeps them awake at low doses, but higher doses can be sedating. The timing of dosing matters. Many patients use oil for baseline relief and flower for breakthrough pain. THC content determines the high and the sedation, while CBD modulates anxiety and inflammation. A balanced 1:1 ratio is common for daytime pain relief.

Key agencies and the legal framework

• Medsafe: the New Zealand Medicines and Medical Devices Safety Authority. It approves finished items and sets the quality standard for the Medicinal Cannabis Scheme. The MCA (Medicinal Cannabis Agency) sits within Medsafe and issues licences.
• The Medicinal Cannabis Scheme: the country’s legal framework for medicinal cannabis, established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 and fully operational from 1 April 2020. It requires items to meet GMP standards, be approved by the Ministry of Health and be prescribed by a doctor. The scheme does not allow recreational use, and it does not permit smoking raw plant material (though vaping dried flower is allowed if prescribed).
• NZ Formulary: lists medicinal cannabis items that can be prescribed, with dosage guidance and product monographs.
• Healthify: national health information service; provides plain-language guides to medicinal cannabis and links to the NZ Formulary.
• Misuse of Drugs Act 1975: the law that classifies cannabis as a controlled drug; the 2018 amendment created the medicinal cannabis scheme.
• New Zealand Medicinal Cannabis Registry: tracks prescriptions and adverse events, run by the Medicinal Cannabis Agency.

Cannabis-based medicines here are regulated as medicines, not dietary supplements, under the Medicines Act 1981. Items must meet GMP and carry a consent from the Minister of Health. The Misuse of Drugs (Medicinal Cannabis) Regulations 2019 set the framework.

Verified research underpinning this advice

• Under the Misuse of Drugs Act 1975, medicinal cannabis is a controlled drug; possession or use outside the prescribing pathway remains illegal.
• The Medicinal Cannabis Scheme (Misuse of Drugs (Medicinal Cannabis) Regulations 2019, in force 1 April 2020) sets GMP, labelling and quality standards; the Ministry of Health and Medsafe administer it.
• The NZ Formulary lists cannabis items with prescriber guidance; clinicians must be familiar with it.
• Healthify (Health Navigator) notes that cannabis can cause drowsiness, impaired coordination, and should be avoided in pregnancy and breastfeeding.
• Medsafe states that CBD and THC items are prescription medicines; unapproved items are not legal.
• Ministry of Health guidance states that the raw cannabis plant (flower) is available by prescription and must be dispensed through a pharmacy.
• Peer-reviewed clinical guidance: a 2021 systematic review in the NZ Medical Journal found moderate-quality evidence for cannabis in chronic pain, but emphasised the lack of long-term safety data; dosing should be individualised and start low and go slow.
• The Medicinal Cannabis Scheme was established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018, which came into force on 1 November 2020, allowing GPs to prescribe and setting quality standards.
• The scheme does not legalise recreational use or possession without a valid authorisation.
• Items must be GMP-certified and approved by the Ministry of Health to be prescribed.
• The Misuse of Drugs (Medicinal Cannabis) Regulations 2019 set the rules for cultivation, manufacture and supply.
• The Medicinal Cannabis Agency oversees the scheme and maintains a public register of notified products.

Making safe storage at home a daily habit

The locked-container rule is only effective if it becomes automatic. Choose a dedicated container that is opaque, lockable and portable enough to keep in a consistent location. A small steel lockbox or a pharmacist-supplied lockable pouch works well. Label it clearly with the product name and the date dispensed, but avoid labelling it in a way that attracts curiosity. Keep the key or combination separate from household keys and out of any shared key bowl.

Check the container each time you use the product. Close and lock it immediately after measuring a dose. Never leave an open jar, oil bottle or vaporiser loaded with flower on a bench, bedside table or windowsill, even for a few minutes. THC-containing edibles pose a particular risk because they resemble ordinary food. Store them in the same locked container, and never in a refrigerator or pantry shelf that others access.

Temperature and light degrade cannabinoids. A cool, dark cupboard or drawer away from heat sources preserves potency. Avoid bathroom cabinets where humidity fluctuates. If you use a portable vaporiser, empty the chamber after each session and lock the device away with the product. A routine that takes less than thirty seconds removes the most common point of failure: an unlocked container left within reach during a distraction.

Recognising adverse effects and when to act

Cannabis can cause drowsiness, impaired coordination, dry mouth, tachycardia and, at high THC doses, anxiety or paranoia. These effects are dose-dependent and more likely when starting a new product or increasing the amount. Track the time of each dose, the product used and any side effects in a simple notebook or app. Share this record with your prescriber at review appointments.

If another person accidentally ingests the product, treat it as a medical emergency. Call 111 immediately if the person is a child, shows confusion, has difficulty breathing or loses consciousness. For non-urgent accidental ingestion, call the National Poisons Centre on 0800 764 766. Do not wait for symptoms to appear before seeking advice. Keep the product packaging to show healthcare staff the exact THC and CBD content.

Do not drive or operate machinery after using THC-containing products until you understand how they affect you. The legal limit for blood THC while driving is effectively zero tolerance under the Land Transport Act 1998. A medicinal cannabis authorisation is not a defence against a charge of driving while impaired. Medsafe and the Ministry of Health advise that patients must not drive if they feel drowsy, dizzy or unable to concentrate, and that impairment can last longer than the subjective high.

When storage rules interact with tenancy and travel

Tenants in rental properties should check their tenancy agreement for clauses about controlled substances. While a valid authorisation makes possession lawful, a landlord may still prohibit smoking or vaping indoors under standard no-smoking terms. Vaping dried flower indoors can trigger smoke-alarm sensors and leave a persistent odour that may breach a tenancy agreement. Use a sealed container and consider vaping outside or near an open window to minimise residue.

Travelling domestically with medicinal cannabis requires the product to remain in its original labelled dispensing container, locked away during transit. Never leave it in a parked car where heat and visibility create security and potency risks. International travel is far more restrictive. Many countries treat cannabis as a prohibited substance regardless of a domestic authorisation. Check the embassy website of the destination country before considering travel, and never assume a local approval applies abroad. The Medicinal Cannabis Agency does not issue export permits for personal use.